Patent Grant
11918936
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 13, 2021, is named W-4192-US03_SL.txt and is 2,337 bytes in size.
The present disclosure relates to the improved performance and dynamic range for analyzing compounds through reduction of non-specific binding. More specifically, the present disclosure relates to the use of a coating to reduce non-specific binding in chromatographic systems to improve performance, e.g., limit of detection, initial performance, and linear dynamic range, for oligonucleotide bioanalysis.
Oligonucleotides are polymeric sequences of nucleotides (RNA, DNA, and their analogs) that are utilized extensively as PCR (polymerase chain reaction) and microarray-based reagents in life science research and DNA-based diagnostic test kits (as primer and probe reagents). With increased frequency, they are being developed as therapeutic drugs for a wide range of disease conditions. Only a few FDA-approved oligonucleotide-based therapeutic drugs are on the market today, but there are over 100 currently in the clinical pipeline and many more in earlier stages of development.
Oligonucleotides developed as therapeutics can take a variety of forms, from antisense oligonucleotides (ASOs), small interfering RNAs (siRNA), small hairpin RNAs (shRNAs), and micro RNAs (miRNAs) that can effect “gene silencing,” which is down-regulating or turning off the expression of specific genes/proteins; to Aptamers that behave like small molecule drugs and bind to specific disease targets; to messenger RNAs (mRNAs) that can be very long, and are being designed to up-regulate expression of a particular protein. To enhance their stability and/or cellular uptake in-vivo, oligonucleotide therapeutics often incorporate chemically-modified nucleotides, are PEGylated, or are otherwise conjugated to other chemical moieties. And like other biologics, the biophysical characteristics and purity of these molecules must be precisely understood and controlled to meet regulatory requirements.
Oligonucleotides are produced through an automated solid-phase synthesis process. Typical lengths range from 20 to 80 nucleotides (mRNAs being an exception, as they can be 1,500 or more nucleotides long). Depending on the application, synthesis scales can vary from nanograms to kilograms. While the synthesis process is efficient, it invariably results in truncated sequences and other process-related by-products/impurities that need to be separated and removed in order to meet purity requirements.
However, due to their polyanionic nature, oligonucleotides are very sticky. They tend to adhere to metallic system components in the fluidic chromatographic path such as preheaters, frits, and column bodies. This can lead to variable recoveries of oligonucleotides.
Non-specific binding of oligonucleotides within chromatographic systems negatively impacts the ability to detect and accurately quantify these molecules. The mechanism of non-specific binding is due to the interaction of the analyte with metallic surfaces in the flow path. Due to the presence of multiple phosphate groups, oligonucleotides are excellent polydentate ligands capable of high affinity metal chelation. This interaction leads to a reduced amount of analyte detected, reduced repeatability of analysis, and inaccurate quantitation. This becomes especially pronounced at lower concentrations where the percentage of analyte that is bound to the surface is very high relative to the total concentration. The impact of performance claims from the analytical methods, such as limit of detection, calibration curve linearity, speed to result, robustness of analysis, and linear dynamic range, are compromised due to this unwanted interaction.
Existing techniques to mitigate these interactions, such as system passivation with nitric acid, are time consuming and only produce temporary performance gains. It is difficult to determine when the system is fully passivated and ready to operate. If attempts are made to obtain data for quantitative studies before full passivation is reached, the lower end of the curve would not be detected because the analyte still has metallic surfaces it can bind to. In order to fully address losses in both linear dynamic range and sensitivity at the lower range of detection, a more permanent solution needs to be implemented. In the present technology, coating of the metallic surfaces defining the flow path offers a pre-passivated system that has demonstrably better limit of detection and initial performance over uncoated systems.
For example, an alkylsilyl coating on the surface area defining the flow path of a chromatographic system can minimize the interactions between oligonucleotides and the metallic surfaces of chromatographic flow paths. Consequently, the coated metallic surfaces improve liquid chromatography separations for oligonucleotides. The use of alkylsilyl coatings on metal flow paths allows the use of metal chromatographic flow paths, which are able to withstand high pressures at fast flow rates, while minimizing the secondary chromatographic interactions between oligonucleotides and the metal. These components made of high pressure material and modified with a coating can be tailored so that the internal flow paths reduce secondary chromatographic interactions.
In one aspect, the present technology relates to a method of separating a sample including oligonucleotides. The method includes providing a chromatographic system having a layer of alkylsilyl on at least a portion of a metallic flow path; injecting the sample comprising oligonucleotides into the chromatographic system; flowing the sample through the chromatographic system; and separating the oligonucleotides. The layer of alkylsilyl can include bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane.
In one aspect, the present technology relates to a method of separating a sample including a low concentration of analyte. The method includes providing a chromatographic system having a layer of alkylsilyl on at least a portion of a metallic flow path; injecting the sample into the alkylsilyl coated metallic flow path of the chromatographic system; flowing the sample through the alkylsilyl coated metallic flow path of the chromatographic system; separating the sample; and detecting at least an amount of the low concentration of the analyte above a minimum expected value.
The above aspect can include one or more of the following features including comprising recovering greater than 80 percent of the analyte when the low concentration of the analyte extends from about 1 ng/mL to about 5 μg/mL. The layer of alkylsilyl can increase recovery of the analyte with the concentration of analyte extending from about 1 ng/mL to about 5 μg/mL. The layer of alkylsilyl can decrease a minimum concentration of a linear dynamic range of the chromatographic system. The layer of alkylsilyl can also increase the linear dynamic range of the chromatographic system. In some embodiments, the linear dynamic range of the chromatographic system with the layer of alkylsilyl is greater than a chromatographic system without an alkylsilyl coating. The layer of alkylsilyl can include bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane.
In a further aspect, the present technology relates to a method of separating a sample. The method includes flowing a first sample comprising oligonucleotides through the system having a fluid-contacting coating on metallic surfaces defining a flow path, wherein the coating comprises an alkylsilyl; separating the first sample; detecting an analyte in the first sample; washing the flow path; flowing a second sample comprising oligonucleotides through the system; separating the second sample; and detecting the second sample, wherein a detected signal from the second sample is within 5% of a detected signal from the first sample and is within 10% of an expected value.
In another aspect, the present technology includes a method of separating a sample. The method includes injecting a first sample comprising oligonucleotides into a system having a fluid-contacting coating on metallic surfaces defining a flow path, wherein the coating comprises an alkylsilyl; flowing the first sample through the system; and detecting oligonucleotides of the first sample at a concentration extending from about 1 ng/mL to about 25 μg/mL (e.g., 1 ng/mL to about 10 μg/mL; 0.1 μg/mL to about 10 μg/mL) when injecting the first sample through the system.
The above aspects and features of the present technology provide numerous advantages over the prior art. For example, in some embodiments, the coated flow path allows for detection of a lower concentration of oligonucleotides, increased accuracy in quantitation of oligonucleotides, the ability to detect oligonucleotides on the first injection, recover an expected amount of oligonucleotides on the first injection, and minimize the amount of injections needed to study a sample.
The technology will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
In general, the present disclosure solves the problem of not being able to tell when chromatographic systems are fully passivated and ready to operate. By addressing the problematic binding of oligonucleotides on metallic surfaces of chromatographic systems, oligonucleotide bioanalysis can begin within the first or second injection of a sample. In addition, the non-binding of the oligonucleotides improves performance such as limit of detection and linear dynamic range. With decreasing the number of injections to prepare the system by passivation, the time and costs for method development can also be decreased.
In addition, coating the system minimizes uncertainty of the chromatographic system performance. Permanent passivation (or at least semi-permanent passivation, i.e., useable lifetime of a consumable) can be provided by the coating. For example, the system does not need to be passivated after each wash, and passivation does not effectively diminish after each wash or flowing. There is not a question of whether the coating is currently effective and diminishing non-specific binding for oligonucleotides. Consequently, the analyte detected can be depended upon as an accurate assessment of the analyte present.
One method of coating is the use of alkylsilyl coatings. In some aspects, the alkylsilyl coating acts a bioinert, low-bind coating to modify a flow path to address flow path interactions with an analyte, such as oligonucleotides. That is, the bioinert, low-bind coating minimizes surface reactions with the metal interacting oligonucleotides and allows oligonucleotides to pass along a flow path without clogging, attaching to surfaces, or change in analyte properties. The reduction/elimination of these interactions is advantageous because it allows for accurate quantification and analysis of a sample containing oligonucleotides.
At least a portion of the wetted surfaces can be coated with an alkylsilyl coating to reduce secondary interactions by tailoring hydrophobicity. The coating can be applied by vapor deposition. As such, methods and devices of the present technology provide the advantage of being able to use high pressure resistant materials (e.g., stainless steel) for the creation of the flow system, but also being able to tailor the wetted surfaces of the fluidic flow path to provide the appropriate hydrophobicity so deleterious interactions or undesirable chemical effects on the sample can be minimized. In some examples, the coating of the flow path is non-binding with respect to the analyte, such as oligonucleotides. Consequently, the analyte, such as oligonucleotides, does not bind to the coating of the flow path.
The alkylsilyl coating can be provided throughout the system from the tubing or fluid conduits 110 extending from the fluid manager system 105 all the way through to the detector 150. The coatings can also be applied to portions of the fluidic fluid path. That is, one may choose to coat one or more components or portions of a component and not the entire fluidic path. For example, the internal portions of the column 125 and its frits 120 and end caps 115 can be coated whereas the remainder of the flow path can be left unmodified. Further, removable/replaceable components can be coated. For example, the vial or sinker 130 containing the sample reservoir can be coated as well as frits 120.
In one aspect, the flow path of the fluidic systems described herein is defined at least in part by an interior surface of tubing. In another aspect, the flow path of the fluidic systems described herein is defined at least in part by an interior surface of microfabricated fluid conduits. In another aspect, the flow path of the fluidic systems described herein is defined at least in part by an interior surface of a column. In another aspect, the flow path of the fluidic systems described herein is defined at least in part by passageways through a frit. In another aspect, the flow path of the fluidic systems described herein is defined at least in part by an interior surface of a sample injection needle. In another aspect, the flow path of the fluidic systems described herein extends from the interior surface of a sample injection needle throughout the interior surface of a column. In another aspect, the flow path extends from a sample reservoir container (e.g., sinker) disposed upstream of and in fluidic communication with the interior surface of a sample injection needle throughout the fluidic system to a connector/port to a detector.
In some embodiments, only the wetted surfaces of the chromatographic column and the components located upstream of the chromatographic column are coated with the alkylsilyl coatings described herein while wetted surfaces located downstream of the column are not coated. The coating can be applied to the wetted surfaces via vapor deposition. Similarly, the “wetted surfaces” of labware or other fluid processing devices may benefit from alkylsilyl coatings described herein. The “wetted surfaces” of these devices not only include the fluidic flow path, but also elements that reside within the fluidic flow path. For example, frits and/or membranes within a solid phase extraction device come in contact with fluidic samples. As a result, not only the internal walls within a solid phase extraction device, but also any frits/membranes are included within the scope of “wetted surfaces.” All “wetted surfaces” or at least some portion of the “wetted surfaces” can be improved or tailored for a particular analysis or procedure by including one or more of the coatings described herein. The term “wetted surfaces” refers to all surfaces within a separation device (e.g., chromatography column, chromatography injection system, chromatography fluid handling system, frit, etc.). The term can also apply to surfaces within labware or other sample preparation devices (e.g., extraction devices) that come into contact with a fluid, especially a fluid containing an analyte of interest.
At least a portion of the wetted surfaces of the fluidic flow path are coated with an alkylsilyl coating. The alkylsilyl coating is inert to at least oligonucleotides in the sample. The alkylsilyl coating can have the Formula I:
R1, R2, R3, R4, R5, and R6 are each independently selected from (C1-C6)alkoxy, —NH(C1-C6)alkyl, —N((C1-C6)alkyl)2, OH, ORA, and halo (i.e., a halogen, for example chloro). RA represents a point of attachment to the interior surfaces of the fluidic system. At least one of R1, R2, R3, R4, R5, and R6 is ORA. X is (C1-C20)alkyl, —O[(CH2)2O]1-20—, —(C1-C10)[NH(CO)NH(C1-C10)]1-20—, or —(C1-C10)[alkylphenyl(C1-C10)alkyl]1-20-.
When used in the context of a chemical formula, a hyphen (“-”) indicates the point of attachment. For example, when X is —[(C1-C10)alkylphenyl(C1-C10)alkyl]1-20-, that means that X is connected to SiR1R2R3 via the (C1-C10)alkyl and connected to SiR4R5R6 via the other (C1-C10)alkyl. This applies to the remaining variables.
In one aspect, X in Formula I is (C1-C15)alkyl, (C1-C12)alkyl, or (C1-C10)alkyl. In some aspects, X in Formula I is methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, t-butyl, pentyl, hexyl, heptyl, nonyl, or decanyl. In other aspect, X in Formula I is ethyl or decanyl.
In one aspect, at least one of R1, R2, R3, R4, R5, and R6 is (C1-C6)alkoxy, e.g., ethoxy, wherein the values for X are described in Formula I or the preceding paragraph. In another aspect, at least two of R1, R2, R3, R4, R5, and R6 is (C1-C6)alkoxy, e.g., ethoxy, wherein the values for X are described in Formula I or the preceding paragraph. In another aspect, at least three of R1, R2, R3, R4, R5, and R6 is (C1-C6)alkoxy, e.g., ethoxy, wherein the values for X are described in Formula I or the preceding paragraph. In another aspect, at least four of R1, R2, R3, R4, R5, and R6 is (C1-C6)alkoxy, e.g., ethoxy, wherein the values for X are described in Formula I or the preceding paragraph. In another aspect, at least five of R1, R2, R3, R4, R5, and R6 is (C1-C6)alkoxy, e.g., ethoxy, wherein the values for X are described in Formula I or the preceding paragraph.
In one aspect, at least one of R1, R2, R3, R4, R5, and R6 is halo, e.g., chloro, wherein the values for X are described in Formula I or the preceding paragraphs above. In another aspect, at least two of R1, R2, R3, R4, R5, and R6 is halo, e.g., chloro, wherein the values for X are described in Formula I or the preceding paragraphs above. In another aspect, at least three of R1, R2, R3, R4, R5, and R6 is halo, e.g., chloro, wherein the values for X are described in Formula I or the preceding paragraphs above. In another aspect, at least four of R1, R2, R3, R4, R5, and R6 is halo, e.g., chloro, wherein the values for X are described in Formula I or the preceding paragraphs above. In another aspect, at least five of R1, R2, R3, R4, R5, and R6 is halo, e.g., chloro, wherein the values for X are described in Formula I or the preceding paragraphs above.
In another aspect, R1, R2, R3, R4, R5, and R6 are each methoxy or chloro.
The alkylsilyl coating of Formula I can have a contact angle of at least about 15°. In some embodiments, the alkylsilyl coating of Formula I can have a contact angle of less than or equal to 30°. The contact angle can be less than or equal to about 90°. In some embodiments, the contact angle of the alkylsilyl coating of Formula I is between about 15° to about 105°. For example, the contact angle of the alkylsilyl coating of Formula I can be about 0°, 5°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, 90°, 95°, 100°, or 105°.
The thickness of the alkylsilyl coating can be at least about 100 Å. For example, the thickness can be between about 100 Å to about 1600 Å. Specifically, the alkylsilyl coating on the walls of the flow path can have a thickness of about 100 Å to about 1600 Å. The thickness of the alkylsilyl coating for Formal I can be about 100 Å, 200 Å, 300 Å, 400 Å, 500 Å, 600 Å, 700 Å, 800 Å, 900 Å, 1000 Å, 1100 Å, 1200 Å, 1300 Å, 1400 Å, 1500 Å or 1600 Å. The thickness of the alkylsilyl coating (e.g., a vapor deposited alkylsilyl coating) can be detected optically by the naked eye. For example, more opaqueness and coloration is indicative of a thicker coating. Thus, coatings with pronounced visual distinction are an embodiment of this technology. From thin to thick, the color changes from yellow, to violet, to blue, to slightly greenish and then back to yellow when coated parts are observed under full-spectrum light, such as sunlight. For example, when the alkylsilyl coating is 300 Å thick, the coating can appear yellow and reflect light with a peak wavelength between 560 and 590 nm. When the alkylsilyl coating is 600 Å thick, the coating can appear violet and reflect light with a peak wavelength between 400 and 450 nm. When the alkylsilyl coating is 1000 Å thick, the coating can appear blue and reflect light with a peak wavelength between 450 and 490 nm. See, e.g., Faucheu et al., Relating Gloss Loss to Topographical Features of a PVDF Coating, Published Oct. 6, 2004; Bohlin, Erik, Surface and Porous Structure of Pigment Coatings, Interactions with flexographic ink and effects of print quality, Dissertation, Karlstad University Studies, 2013:49.
In some examples, coating the flow path includes uniformly distributing the coating about the flow path, such that the walls defining the flow path are entirely coated. Uniformly distributing the coating can provide a uniform thickness of the coating about the flow path. In general, the coating uniformly covers the wetted surfaces such that there are no “bare” or uncoated spots.
In one aspect, the vapor deposited coating of Formula I is the product of vapor deposited bis(trichlorosilyl)ethane, bis(trimethoxysilyl)ethane, bis(trichlorosilyl)octane, bis(trimethoxysilyl)octane, bis(trimethoxysilyl)hexane, and bis(trichlorosilyl)hexane.
In some aspects, at least a portion of the wetted surfaces are coated with multiple layers of the same or different alkysilyls, where the thickness of the alkylsilyl coatings correlate with the number of layering steps performed (e.g., the number of deposited layers of alkylsilyl coating on wetted surfaces (e.g., internal surfaces of the fluidic flow path of the chromatographic system/device or internal surfaces or fluid interfacing/contacting surfaces of labware or other analytical devices, such as frits within a solid phase extraction device together with interior walls of the solid phase extraction device). In this manner, increasingly thick bioinert coatings can be produced and tailored to achieve desirable separations.
The chromatographic device can have a second alkylsilyl coating in direct contact with the alkylsilyl coating of Formula I. The second alkylsilyl coating has the Formula II
wherein R7, R8, and R9 are each independently selected from —NH(C1-C6)alkyl, —N[(C1-C6)alkyl]2, (C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkenyl, OH, and halo; R10 is selected from (C1-C6)alkyl, —ORB, —[O(C1-C3)alkyl]1-10O(C1-C6)alkyl, —[O(C1-C3)alkyl]1-10OH and phenyl. (C1-C6)alkyl is optionally substituted with one or more halo. The phenyl is optionally substituted with one or more groups selected from (C1-C3)alkyl, hydroxyl, fluorine, chlorine, bromine, cyano, —C(O)NH2, and carboxyl. RB is —(C1-C3)alkyloxirane, —(C1-C3)alkyl-3,4-epoxycyclohexyl, or —(C1-C4)alkylOH. The hashed bond to R10 represents an optional additional covalent bond between R10 and the carbon bridging the silyl group to form an alkene, provided y is not 0. y is an integer from 0 to 20.
In one aspect, y in Formula II is an integer from 1 to 15. In another aspect, y in Formula II is an integer from 1 to 12. In another aspect, y in Formula II is an integer from 1 to 10. In another aspect, y in Formula II is an integer from 2 to 9.
In one aspect R10 in Formula II is methyl and y is as described above for Formula II or the preceding paragraph.
In one aspect, R7, R8, and R9 in Formula II are each the same, wherein R10 and y are as described above. In one aspect, R7, R8, and R9 are each halo (e.g., chloro) or (C1-C6)alkoxy such as methoxy, wherein R10 and y are as described above.
In one aspect, y in Formula II is 9, R10 is methyl, and R7, R8, and R9 are each ethoxy or chloro.
In one aspect, the coating of the formula II is n-decyltrichlorosilane, (3-glycidyloxypropyl)trimethoxysilane (GPTMS), (3-glycidyloxypropyl)trimethoxysilane (GPTMS) followed by hydrolysis, 2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane, trimethylchlorosilane, trimethyldimethyaminosilane, methoxy-polyethyleneoxy(3)silane propyltrichlorosilane, propyltrimethoxysilane, (heptadecafluoro-1,1,2,2-tetrahydrodecyl)tris(dimethylamino)silane, (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trischlorosilane, (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane vinyltrichlorosilane, vinyltrimethoxysilane, allyltrichlorosilane, 2-[methoxy(polyethyleneoxy)3propyl]trichlorosilane, 2-[methoxy(polyethyleneoxy)3propyl]trimethoxysilane, or 2-[methoxy(polyethyleneoxy)3propyl]tris(dimethylamino)silane.
The alkylsilyl coating of Formula I and II can have a contact angle of at least about 15°. In some embodiments, the alkylsilyl coating of Formula I and II can have a contact angle of less than or equal to 105°. The contact angle can be less than or equal to about 90°. In some embodiments, the contact angle of the alkylsilyl coating of Formula I and II is between about 15° to about 105°. For example, the contact angle of the alkylsilyl coating of Formula I and II can be about 0°, 5°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, 90°, 95°, 100°, or 105°.
The thickness of the multi-layered alkylsilyl coating can be at least about 100 Å. For example, the thickness can be between about 100 Å to about 1600 Å. The thickness of the multi-layered alkylsilyl coating for Formal I can be about 100 Å, 200 Å, 300 Å, 400 Å, 500 Å, 600 Å, 700 Å, 800 Å, 900 Å, 1000 Å, 1100 Å, 1200 Å, 1300 Å, 1400 Å, 1500 Å or 1600 Å.
In one aspect, the alkylsilyl coating of Formula I is bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula II is (3-glycidyloxypropyl)trimethoxysilane. In another aspect, the alkylsilyl coating of Formula I is bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula II is (3-glycidyloxypropyl)trimethoxysilane followed by hydrolysis. In one aspect, the alkylsilyl coating of Formula I is bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula II is n-decyltrichlorosilane. The alkylsilyl coating of Formula I can be bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula II can be trimethylchlorosilane or trimethyldimethyaminosilane. In one aspect, the alkylsilyl coating of Formula I is bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula II is methoxy-polyethyleneoxy(3) propyl tricholorosilane or methoxy-polyethyleneoxy(3) propyl trimethoxysilane.
The chromatographic device can have an alkylsilyl coating in direct contact with the alkylsilyl coating of Formula III in direct contact with the alkylsilyl coating of Formula I.
R11, R12, R13, R14, R15, and R16 are each independently selected from (C1-C6)alkoxy, —NH(C1-C6)alkyl, —N((C1-C6)alkyl)2, OH, and halo (i.e., a halogen, for example, chloro). Z is (C1-C20)alkyl, —O[(CH2)2O]1-20—, —(C1-C10)[NH(CO)NH(C1-C10)]1-20—, or —(C1-C10)[alkylphenyl(C1-C10)alkyl]1-20-.
In some aspects, Z in Formula III is (C1-C10)alkyl; and R1, R2, R3, R4, R5, and R6 are each methoxy or chloro. In other aspects, Z in Formula III is (C2-C10)alkyl. In other aspects, Z in Formula III is ethyl.
In the layered alkylsilyl coating of Formula I and Formula III, Formula I and Formula III can be the same (for example, C2C2) or Formula I and Formula III can be different. Formula III is attached directly to the coating of Formula I, i.e., in Formula III, there is no point of attachment to the interior of the fluidic system; instead Formula III is deposited directly on Formula I.
The alkylsilyl coating of Formula III can be bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane. The alkylsilyl coating of Formula I can be bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane and the alkylsilyl coating of Formula III can be bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane.
The alkylsilyl coating of Formula I and III can have a contact angle of at least about 15°. In some embodiments, the alkylsilyl coating of Formula I and III can have a contact angle of less than or equal to 105°. The contact angle can be less than or equal to about 90°. In some embodiments, the contact angle of the alkylsilyl coating of Formula I and III is between about 15° to about 105°. For example, the contact angle of the alkylsilyl coating of Formula I and III can be about 0°, 5°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, 90°, 95°, 100°, or 105°.
The thickness of the multi-layered alkylsilyl coating can be at least about 100 Å. For example, the thickness can be between about 100 Å to about 1600 Å. The thickness of the multi-layered alkylsilyl coating for Formal I can be about 100 Å, 200 Å, 300 Å, 400 Å, 500 Å, 600 Å, 700 Å, 800 Å, 900 Å, 1000 Å, 1100 Å, 1200 Å, 1300 Å, 1400 Å, 1500 Å or 1600 Å.
In one aspect, the alkylsilyl coating of Formula II is applied directly to wetted surfaces of the fluidic flow path. Therefore, in some embodiments, one of R7, R8, and R9 of Formula II can also include ORA, where RA represents a point of attachment to the interior surfaces (e.g., wetted surfaces) of the fluidic system. In other embodiments, R7, R8, and R9 of the alkylsilyl coating of Formula II does not include ORA, by the alkylsilyl coating of Formula II is deposited directly onto wetted surfaces of the fluidic flow path that have been pre-treated with, for example, a plasma.
In one aspect, stainless steel flow path components, including but not limited to tubing, microfabricated fluid conduits, column fits, column inlet tubing, and sample injection needles, are coated via vapor deposition with one or more of the disclosed alkylsilyls. In one aspect, these coated components are annealed to alter their chemical or physical properties.
Exemplary coatings with their respective approximate thickness and contact angle are provided in Table 1.
Referring to VPD #1 (C2-GPTMS-OH), the first coating layer, C2 shown below, is a layer according to Formula I, described above.
The second layer of VPD #1, GPTMS-OH, shown below, is a layer according to Formula II.
VPD #3 (C2-C2) is an example of a coating of Formula I and then a coating for Formula III.
VPD #7 (C2C10) is another example of a coating of Formula I and a second layer of Formula II. The structure of bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane (C2) is shown above. The structure of C10 is shown below.
VPD #11 (C2C3) is another example of a coating of Formula I and a second layer of Formula II. The structure of bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane (C2) is shown above. The structure of C3 is shown below.
VPD #13 is another example of a coating of Formula I and a second layer of Formula II. The structure of bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane (C2) is shown above. The structure of methoxy-polyethyleneoxy(3)propyl trichlorosilane (PEO) is shown below.
Alternatively, commercially available vapor deposition coatings can be used in the disclosed systems, devices, and methods, including but not limited to Dursan® and Dursox® (commercially available from SilcoTek Corporation, Bellefonte, PA).
In one aspect, the alkylsilyl coatings described herein enhance the corrosion performance of metals, e.g., as in metallic chromatography columns. Depending on the denseness and thickness, the coatings act as a barrier, thereby preventing water and corrosive molecules from reacting with the base metal. The alkylsilyl coatings can be hydrophobic. While increasing the hydrophobicity and density improves the corrosion performance, even coatings derived from C2 and GPTMS (C2-GPTMS) followed by hydrolysis to form C2-GPTMS-OH shows a 10× improvement in the ASTM G48 Method A pitting corrosion. In terms of most corrosion resistant to least, the ranking is the material formed from VPD #7>2>1 (bis(trichlorosilyl)ethane or bis(trimethoxysilyl)ethane as a first layer followed by GPTMS then hydrolysis to form GPTMS-OH as a second layer). This also correlates to hydrophobicity rankings.
The coatings described above can be used to tailor a fluidic flow path of a chromatography system for the separation of a sample. The coatings can be vapor deposited. In general, the deposited coatings can be used to adjust the hydrophobicity of internal surfaces of the fluidic flow path that come into contact with a fluid (i.e. wetted surfaces or surfaces coming into contact with the mobile phase and/or sample/analyte). By coating wetted surfaces of one or more components of a flow path within a chromatography system, a user can tailor the wetted surfaces to provide a desired interaction (i.e., a lack of interaction) between the flow path and fluids therein (including any sample, such as a sample containing oligonucleotides, within the fluid).
Non-specific binding of oligonucleotides within chromatographic systems negatively impacts the ability to detect and accurately quantify these molecules. The mechanism of non-specific binding is due to the interaction of the analyte with metallic surfaces in the flow path. The present disclosure relates to the use of a coating to reduce non-specific binding in chromatographic systems to improve performance, e.g., limit of detection, initial performance, peak shape, retention times, accurate quantitation, repeatability of analysis, speed to result, and linear dynamic range, for oligonucleotide bioanalysis.
In one aspect, an effective coating is produced from a low temperature, vacuum-assisted vapor deposition process. In one aspect, an oxygen plasma pretreatment step precedes the coating deposition. The oxygen plasma removes organic compounds and improves surface wettability for the coatings. Time, temperature, and pressure are controlled for each processing step. Each coating run can use a silicon wafer to monitor the thickness and contact angle of the resultant coating. Ellipsometry can be used to measure the coating thickness, and an optical goniometer can be used to measure the contact angle of the coating. A post coating annealing step can be utilized to increase coating cross-linking and increase coating hydrophobicity.
Further information regarding deposition of coatings in accordance with the present technology is available in US 2019/0086371, which is hereby incorporated by reference.
Next, an infiltration step (210) is initiated. A vaporized source of an alkylsilyl compound (e.g., the alkylsilyl compounds of Formulas I, II and/or III) is infiltrated into the flow path. The vaporized source is free to travel throughout and along the internal surfaces of the flow path. Temperature and/or pressure is controlled during infiltration such that the vaporized source is allowed to permeate throughout the internal flow path and to deposit a coating from the vaporized source on the exposed surface (e.g., wetted surfaces) of the flow path as shown in step 215. Additional steps can be taken to further tailor the flow path. For example, after the coating is deposited, it can be heat treated or annealed (step 220) to create cross linking within the deposited coating and/or to adjust the contact angle or hydrophobicity of the coating. Additionally or alternatively, a second coating of alkylsilyl compound (having the same or different form) can be deposited by infiltrating a vaporized source into the flow path and depositing a second or additional layers in contact with the first deposited layer as shown in step 225. After the deposition of each coating layer, an annealing step can occur. Numerous infiltration and annealing steps can be provided to tailor the flow path accordingly (step 230).
In some embodiments, in addition to assessing the polarity of oligonucleotides, the polarity of a stationary phase to be used to separate the oligonucleotides (e.g., stationary phase to be included in at least a portion of the fluidic flow path) is also assessed. A chromatographic media can be selected based on oligonucleotides in the sample. Understanding the polarity of both the oligonucleotides and the stationary phase is used in certain embodiments by the operator to select the desired coating chemistry and contact angle in step 310. The components to be tailored can then be positioned within a chemical infiltration system with environmental control (e.g., pressure, atmosphere, temperature, etc.) and precursor materials are infiltrated into the flow path of the component to deposit one or more coatings along the wetted surfaces to adjust the hydrophobicity as shown in step 315. During any one of infiltration, deposition, and condition steps (e.g. annealing), coatings deposited from the infiltration system can be monitored and if necessary precursors and or depositing conditions can be adjusted if required allowing for fine tuning of coating properties. The alkylsilyl coating material selected in step 310 can be the alkylsilyl compounds of Formulas I, II and/or III. For example, the alkylsilyl coating could be an organosilica coating with Formula I (C2 coating described above). The alkylsilyl coating need not be selected from these formulas. That is, other materials are available for use as the coating material. A possible coating material includes any deposited coating that is hydrophobic.
The method also includes adjusting a hydrophobicity of the wetted surfaces of the fluidic flow path by vapor depositing the alkylsilyl coating onto the wetted surfaces of the fluidic flow path. In some embodiments, the hydrophobicity of the wetted surfaces is adjusted by adjusting the contact angle of the alkylsilyl coating. For example, the contact angle of the alkylsilyl coating can be between about 0° to about 105°.
The analyte in the sample can be retained with a retentivity within 10% of the retentivity attributable to the chromatography media. In some embodiments, the sample can be retained with a retentivity within 5% or within 1% of the retentivity attributable to the chromatography media. Therefore, the alkylsilyl coating solves the problem of metal interaction between the analyte and the metal chromatographic materials without introducing any secondary reactions that would have a negative effect on the quality of the separation. The alkylsilyl coating does not impart any retention mechanism on the analyte of interest, making the coating inert to the analyte of interest and low-binding.
In some embodiments, the alkylsilyl coating is modified with a silanizing reagent to obtain a desired thickness of the alkylsilyl coating. The silanizing reagent can be a non-volatile zwitterion. The non-volatile zwitterion can be sulfobetaine or carboxybetaine. In some embodiments, the silanizing reagent is an acidic or basic silane. The silanizing reagent can introduce polyethylene oxide moieties, such as methoxy-polyethyleneoxy(6-9)silane, the structure of which is shown below.
In some aspects, the method of tailoring a fluidic flow path for separation of a sample includes pretreating the wetted surfaces of the flow path with a plasma prior to depositing the first coating, annealing the first coating at a temperature to increase cross-linking in the first coating, and/or annealing the first coating at a temperature to alter hydrophobicity.
Non-Specific Binding
Due to prevention of non-specific binding of oligonucleotides in the flow path, a sample with a low concentration of oligonucleotides can still recover oligonucleotides. This is especially pronounced at lower concentrations because the percentage of analyte that is bound to the surface is high relative to the total concentration. In some examples, chromatographic systems can recover greater than 80 percent of the analyte when the low concentration of the analyte extends from about 1 ng/mL to about 25 μg/mL.
In some examples, chromatographic systems can recover greater than 80, 85, 90, or percent of the analyte in a first injection.
The present technology provides an advantage over the non-coated flow paths in that such low concentrations are usually not detectable. That is, the low concentration samples easily bind to the metallic surfaces—and passivation would take too long or require too much sample. injecting the sample is a first injection, and detecting includes detecting the analyte after the first injection when the low concentration of the analyte extends from about 1 ng/mL to about 5 μg/mL or from 1 ng/mL to about 25 μg/mL.
The present technology provides an advantage over the non-coated flow paths in that on the first injection an analyte can be recovered. In addition, not only can an analyte be recovered but the amount of analyte recovered is an accurate representation of the amount of analyte in the sample. For example, coating the flow path of the chromatographic system increases recovery of the analyte with the concentration of the analyte extending from about 1 ng/mL to about 5 μg/mL. As a comparison, recovery of oligonucleotides on a first injection can increase by 20 percent (or more, e.g., 25%, 30%, 40%, 50%, 60%, 70%, 80, 85%, 90%, 100%) by coating the flow path of the chromatographic system.
Without wishing to being bound by theory, the mechanism of non-specific binding is due to the interaction of the analyte with metallic surfaces in the flow path. Due to the presence of multiple phosphate groups, oligonucleotides are excellent polydentate ligands capable of high affinity metal chelation. This interaction leads to a reduced amount of analyte detected and inaccurate quantitation. This becomes especially pronounced at lower concentrations where the percentage of analyte that is bound to the surface is very high relative to the total concentration. The impact of performance claims from the analytical methods, such as limit of detection and linear dynamic range, are compromised due to this unwanted interaction.
The present technology provides an advantage over the non-coated flow paths in that coating the flow path of the chromatographic system increases a linear dynamic range of the chromatographic system. A linear dynamic range of the chromatographic system with the coating is greater than a chromatographic system without the coating. For example, coating the chromatographic system can decrease a minimum concentration of a linear dynamic range of the chromatographic system. With a constant maximum concentration of the linear dynamic range of the chromatographic system, the linear dynamic range will be increased because the minimum concentration of the linear dynamic range has decreased. Stated another way, the linear dynamic range increases because the maximum concentration stays constant while the minimum increases.
As stated herein, a first injection can have a high percentage of analyte recovered. In some examples, the amount of analyte recovered will remain substantially constant over the first injections. Consequently, a minimum of a linear dynamic range of the chromatographic system can remains substantially similar over the first 50 injections.
Non-specific binding (e.g., mostly on metallic frits, partially on column hardware and tubing) often alters the chromatographic peak shape. Peaks can tail to the extent it is difficult to integrate them. By coating the fluid flow path to prevent non-specific binding, chromatographic peak shape will be more accurate on the first injection. Consequently, chromatographic peak shape can be predicted for samples with known oligonucleotides. The actual versus expected chromatographic peak shape can be compared. In some examples, a chromatographic peak shape of the analyte of the separated sample can be substantially similar to a reference chromatographic peak shape. Also, coating the flow path of the liquid chromatography column increases the similarity between a chromatographic peak shape of the analyte of the separated sample and a reference chromatographic peak shape.
In addition, the coating (e.g., an alkylsilyl coating) in some embodiments does not produce any changes to peak width. The analyte in the sample has a peak width that is within 10%, 5%, or 1% of the peak width attributable to the chromatographic media.
Also, non-specific binding will shift retention times (non-specific binding contributes to retention), so the retention time can be hard to control as the column is being passivated by injections of sample. Thus, by coating the flow paths (e.g., entire wetted flow path including injection mechanisms, frits, connectors, etc.), a permanent (or semi-permanent) passivation is created—that does not wash away or dissipate during wash cycles or after stopping flow of a sample.
LC/MS data for a fully thiolated 25-mer (GEM 91 oligonucleotides) was acquired using both coated and uncoated systems and the results were compared (
Additional improvements over the uncoated technology are also achieved by the present disclosure. For example, significant gains are achieved with respect to the limit of quantitation (LOQ). Specifically, a calibration curve for an uncoated flow path is known to start out at a very low concentration and increase. The data of
The performance gains as shown in Example 1 are further demonstrated when injecting a higher concentration sample.
These samples, injected immediately after the lower concentration samples from Example 1, show that the uncoated system (triangle) required nine injections to equilibrate and reach the performance of a fully passivated system (triangle). As indicated previously, the coated system (diamond) was able to reach the performance specification on its first injection.
MISER enables fast analyses and visualization of series of injections.
Experimental set-up including bio-inert hardware: H-Class Bio modified with a coating to create a low bind surfaces (LBS). LBS are based on chemical coating on metallic surfaces. Stainless steel or titanium frits were coated by C2 or C2C10 coatings and then investigated. The coated and uncoated frits housed in the holder were placed in the mobile phase flow path in place of the column.
LBS can improve analyte recovery and peak shape. Bio-inert LC systems can include LBS as the wetted surfaces. LBS is applicable to column hardware.
For Example 3, no column was used. All the observed sample loss is due to single frit. The frit was chosen because it has the most significant surface area—the most obvious impact on sample recovery. The mobile phase was 10 mM ammonium acetate, pH ˜7 in 50% ACN.
For Example 4, conventional column (two stainless steel frits) was used for separation of oligonucleotides.
Prior to coating, all metal components are passivated according to a nitric acid passivation. Passivated parts and a silicon wafer are then introduced to the vapor deposition chamber and vacuum is established. The first step is a 15 minute, 200 Watt, 200 cc/min oxygen plasma cleaning step. Next is the first vapor deposition cycle. Each vapor deposition cycle contains a silane vapor deposition, followed by the introduction of water vapor for silane hydrolysis. The silane vapor is delivered at a pressure of 2.0 Torr for 5 seconds, and then the water vapor is delivered at a pressure of 50 Torr for 5 seconds. Following delivery, the silane and water is left to react with the substrate for 15 minutes. This cycle is repeated to produce the desired number of layers and coating thickness. An additional processing cycle can be implemented to functionalize the coating with yet another silane. Moreover, a post coating annealing step can be used to further cross-link and increase the hydrophobicity of the coating. Typically, the annealing cycle involves subjecting the coating to 200° C. for 3 hours under vacuum.
A silicon wafer is used as a coupon to measure the thickness and contact angle of the coating. To measure the thickness, a Gaertner Scientific Corporation stokes ellipsometer model LSE is used. By analyzing the change in polarization of light, and comparing to a model, the film thickness can be established. To measure the contact angle, a Ramé-Hart goniometer model 190 is used. After dropping a controlled amount of water onto a perfectly level silicon wafer, optical techniques are used to measure the contact angle.
Prior to coating, all metal components are passivated according to a nitric acid passivation. Passivated parts and a silicon wafer are then introduced to the vapor deposition chamber and vacuum is established. The first step is a 15 minute, 200 Watt, 200 cc/min oxygen plasma cleaning step. Next is the first vapor deposition cycle. Each vapor deposition cycle contains a silane vapor deposition, followed by the introduction of water vapor for silane hydrolysis. The silane vapor is delivered at a pressure of 2.0 Torr for 5 seconds, and then the water vapor is delivered at a pressure of 50 Torr for 5 seconds. Following delivery, the silane and water is left to react with the substrate for 15 minutes. This cycle is repeated to produce the desired number of layers and coating thickness. In this example, the bis(trichlorosilyl)ethane silane is used to build up an adhesion or primer layer of approximately 800 Å. After C2 deposition, the 3-(glycidoxypropyl)trimethoxysilane is delivered anhydrously to a pressure of 0.4 Torr in the vapor deposition chamber. This silane vapor is left to react with the C2 coated substrate for one hour. This process results in an epoxide terminated coating, with a contact angle of 50°. After deposition, the next step is to hydrolyze the epoxide groups. This is performed either in the liquid phase or the vapor phase, with 0.1M acetic acid. After epoxide hydrolysis, the contact angle is <20°. Contact angle measurements are taken on a silicon wafer using a Ramé-Hart goniometer model 190.
Testing has shown that flow paths modified with the vapor deposition coatings of the present disclosure are also helpful in improving oligonucleotide separations. Example 5 provides evidence of such as observed in the form of improved recoveries and more accurate profiling of a sample's composition, particularly with respect to the first chromatograms obtained with a column.
In this work, a mixture of 15 (SEQ ID NO: 2), 20 (SEQ ID NO: 3), 25 (SEQ ID NO: 4), 30 (SEQ ID NO: 5), 35 (SEQ ID NO: 6) and 40-mer (SEQ ID NO: 7) deoxythymidine was separated using columns constructed from a 1.7 μm organosilica 130 Å C18 bonded stationary phase packed into either uncoated or vapor deposition coated hardware. Separations were performed with an Ultra High Performance Liquid Chromatography (UHPLC) system such as a system commercially available from Waters Corp. (Milford, MA) as an ACQUITY™ UPLC® H-Class Bio instrument according to the experimental conditions outlined below.
LC Conditions
Columns: 1.7 μm organosilica 130 Å C18 bonded stationary phase in a 2.1×50 mm column dimension
Sample: 15 (SEQ ID NO: 2), 20 (SEQ ID NO: 3), 25 (SEQ ID NO: 4), 30 (SEQ ID NO: 5), 35 (SEQ ID NO: 6) and 40-mer (SEQ ID NO: 7) deoxythymidine (0.5 pmol/μL)
Column Temperature: 60° C.
Flow Rate: 0.2 mL/min
Mobile Phase A: 400 mM HFIP, 15 mM TEA in water
Mobile Phase B: 400 mM HFIP, 15 mM TEA in methanol
Gradient: 18 to 28% B in 5 min
Injection volume: 10 μL
UV Detection: 260 nm
Non-specific binding of oligonucleotides within chromatographic systems negatively impacts the ability to detect and accurately quantify these molecules. The mechanism of non-specific binding is due to the interaction of the analyte with metallic surfaces in the flow path. The present disclosure relates to the use of a coating to reduce non-specific binding in chromatographic systems to improve performance, e.g., limit of detection, initial performance, peak shape, retention times, accurate quantitation, repeatability of analysis, speed to result, and linear dynamic range, for oligonucleotide bioanalysis.
A standard curve of a 21mer ssRNA (5′ rArUrG rGrArA rUrArC rUrCrU rUrGrG rUrUrA rCTT 3′ (SEQ ID NO: 1)) was prepared in water at a concentration range of 1-100 μg/mL.
LC Conditions
MPA: 10 mM TEAA
MPB: 100 mM TEAA, 20% Acetonitrile pH 9.2
Injection volume: 5 μL
System: HClass Bio FTN
Column temp: 30° C.
UV detection at 260 nm
The results demonstrate (
Interactions of analytes with metal surfaces in Ultra High Performance Liquid Chromatography (UHPLC) instruments and columns may cause a range of deleterious effects ranging from peak tailing to complete loss. These effects are due to interactions of certain analytes with the metal oxide layer on the surface of the metal components. A barrier technology has been applied to the metal surfaces in UHPLC instruments and columns to mitigate these interactions. A hybrid organic/inorganic barrier based on an ethylene-bridged siloxane structure was developed for use with reversed-phase and hydrophilic interaction chromatography. The performance of UHPLC instruments and columns that incorporate this barrier technology have been characterized and the results have been compared to those obtained using conventional instruments and columns. Improved performance has been shown when using the barrier technology for separations of an oligonucleotide. The barrier technology was found to result in improved analyte recovery and peak shape, particularly when using low analyte mass loads and acidic mobile phases. The results suggest that this technology will be particularly impactful in UHPLC/MS investigations of metal-sensitive analytes.
For the last fifty years, stainless steel has been the most commonly used construction material for HPLC instruments and columns. The combination of high strength, compatibility with a wide range of chemicals, manufacturability and low cost make it an excellent material for many applications. However, stainless steel hardware can negatively impact the peak shape and recovery of some analytes. Analytes that show these effects typically contain functional groups such as phosphate and carboxylate groups that can form chelation complexes with iron and other transition metal ions. Stainless steel is susceptible to corrosion, particularly when exposed to acidic and/or halide-containing mobile phases, and corroded surfaces may be particularly prone to interacting with certain analytes. Alternative metals such as titanium and MP35N (a nickel-cobalt alloy) have been used for some applications because of their improved corrosion resistance, but still cause deleterious chromatographic effects for certain analytes. The engineering plastic polyether ether ketone (PEEK) has been employed to avoid these effects, but suffers from limited pressure resistance and some solvent incompatibilities. PEEK is also relatively hydrophobic and may require conditioning to avoid losses of hydrophobic analytes.
An alternative approach to mitigate interactions of analytes with metal surfaces is to add chelators such as ethylenediaminetetraacetic acid to the mobile phase or sample. Volatile chelators such as citric acid, acetylacetone and medronic acid have been used for LC/MS analyses. However, the use of chelators can negatively impact chromatographic selectivity and MS sensitivity. To address these issues, the use of a hybrid organic/inorganic barrier surface applied to the metal substrates in UHPLC instruments and columns was explored. A hybrid barrier surface based on an ethylene-bridged siloxane polymer has been found to be well-suited for reversed-phase (RP) and hydrophilic interaction chromatography (HILIC). Evaluations of the performance of UHPLC instruments and columns incorporating this hybrid barrier surface (HBS) technology relative to conventional instruments and columns were explored.
Reagents and Standards. Trecovirsen, a 25-mer phosphorothioate oligonucleotide with the sequence CTC TCG CAC CCA TCT CTC TCC TTC T (SEQ ID NO: 8), was acquired from Integrated DNA Technologies, Inc. (Coralville, IA). Undoped, polished, <100> orientation silicon wafers were obtained from Silicon Materials, Inc. (Pittsburgh, PA).
Instrumentation. A Model 190 CA Goniometer (available from ramé-hart instrument co., Succasunna, NJ) was used to measure contact angles on silicon wafers to which the hybrid barrier surface was applied.
Chromatographic Conditions—Oligonucleotide Separations. Trecovirsen was analyzed by LC-UV using UHPLC such as a system commercially available from Waters Corp. (Milford, MA) as HBS-modified ACQUITY™ UPLC® H-Class Bio System. Separations were performed on three sets of 1.7 μm BEH C18 2.1×50 mm stainless steel columns, using a mobile phase comprised of 15 mM triethylamine, 400 mM HFIP in water (mobile phase A) and a 50:50 (v/v) solution of mobile phase A and methanol (mobile phase B). Separations were also performed using columns of the same dimensions constructed with hardware modified with the HBS and packed with the same batch of stationary phase for comparison testing. Separations were run at a temperature of 60° C., a flow rate of 0.2 mL/min, and a gradient from 0.5-40% B in 12 min, followed by 40-80% B in 2 min. Samples were tested before and after conditioning the columns with 0.2 μg high mass load injections of trecovirsen. Prior to column conditioning, four injections of trecovirsen at a mass load of 1.5 ng were made. Next, the columns were conditioned by injecting 0.2 μg of trecovirsen followed by 10 μL of water to ensure no carryover of the oligonucleotide. This was followed by a fifth 1.5 ng mass load injection of trecovirsen to assess analyte recovery on the conditioned columns. Analyses were performed with UV detection at 260 nm using MassLynx™ 4.1 (available from Waters Corp., Milford, MA) for data acquisition and UNIFI 1.8 (available from Waters Corp., Milford, MA) for data analysis. A Xevo® TQ-XS mass spectrometer (available from Waters Corp., Milford, MA) was used for MS detection with a capillary voltage of 2.0 kV, sampling cone at 45, source offset at 30, a source temperature of 150° C., a desolvation temperature of 600° C., desolvation gas flow set at 1000 L/h, and a collision energy set at 5 eV.
Evaluation for Oligonucleotide Separations. The utility of UHPLC columns constructed with the HBS for the analysis of oligonucleotides was investigated. The analyte chosen for Example 11 was trecovirsen, a 25-mer antisense oligonucleotide phosphorothioate that has been studied as a treatment for HIV-1. The UHPLC system used for this experiment had components that were treated with the HBS. An ion-pairing mobile phase system containing 15 mM triethylamine (TEA), 400 mM HFIP and methanol was employed. The same lot of stationary phase was packed in both stainless steel columns and columns constructed using the HBS. Three columns of each type were evaluated. The initial performance from the first four injections of 1.5 ng of trecovirsen was evaluated before conditioning the columns with a high mass load (200 ng) of this oligonucleotide. A fifth injection was then made in order to determine whether conditioning gave any improvements in chromatographic performance.
Representative UV chromatograms resulting from the fourth and fifth injections are shown in
Further differences in the chromatography were noticed in the resolution of co-eluting, lower abundant oligonucleotide species, as shown in
The HBS technology described here provides a means to improve UHPLC analyses of analytes that interact with metal surfaces. High recoveries and more symmetric peaks have been demonstrated to be obtainable using UHPLC systems and columns that incorporate this technology, even for challenging analytes such as a phosphorothioated oligonucleotide. In addition, significant benefits have been observed for analytes containing multiple carboxylate groups, such as citric acid and acidic peptides.
HBS UHPLC systems and columns have been shown to give the biggest improvement over their standard counterparts at low mass loads. This suggests that methods employing UHPLC/MS will benefit greatly from this technology, particularly when trace level quantitative measurements are needed. Work is in progress to further demonstrate the range of applications that benefit from this technology.
This application claims priority to U.S. Provisional Application No. 62/962,487 filed on Jan. 17, 2020 and U.S. Provisional Application No. 63/058,737 filed on Jul. 30, 2020, the contents of each are incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2801186 | Alexander et al. | Jul 1957 | A |
| 4207188 | Tsuda et al. | Jun 1980 | A |
| 4708782 | Andresen et al. | Nov 1987 | A |
| 4711820 | Arkles et al. | Dec 1987 | A |
| 4833093 | Malmqvist et al. | May 1989 | A |
| 4945282 | Kawamura et al. | Jul 1990 | A |
| 4999162 | Wells et al. | Mar 1991 | A |
| 5002794 | Ratner et al. | Mar 1991 | A |
| 5153072 | Ratner et al. | Oct 1992 | A |
| 5470463 | Girot et al. | Nov 1995 | A |
| 5550184 | Halling | Aug 1996 | A |
| 5595813 | Ogawa et al. | Jan 1997 | A |
| 5643436 | Ogawa et al. | Jul 1997 | A |
| 5658732 | Ebersole et al. | Aug 1997 | A |
| 5688855 | Stoy et al. | Nov 1997 | A |
| 5856192 | Bloch | Jan 1999 | A |
| 5876753 | Timmons et al. | Mar 1999 | A |
| 5877028 | Chandler et al. | Mar 1999 | A |
| 5909314 | Oka et al. | Jun 1999 | A |
| 6013372 | Hayakawa et al. | Jan 2000 | A |
| 6054227 | Greenberg et al. | Apr 2000 | A |
| 6074981 | Tada et al. | Jun 2000 | A |
| 6121608 | Takada et al. | Sep 2000 | A |
| 6194346 | Tada et al. | Feb 2001 | B1 |
| 6207263 | Takematsu et al. | Mar 2001 | B1 |
| RE37183 | Kawamura et al. | May 2001 | E |
| 6265026 | Wang | Jul 2001 | B1 |
| 6277489 | Abbott et al. | Aug 2001 | B1 |
| 6306506 | Timmons et al. | Oct 2001 | B1 |
| 6329024 | Timmons et al. | Dec 2001 | B1 |
| 6329209 | Wagner et al. | Dec 2001 | B1 |
| 6337129 | Watanabe et al. | Jan 2002 | B1 |
| 6340404 | Oka et al. | Jan 2002 | B1 |
| 6383642 | Le Bellac et al. | May 2002 | B1 |
| 6436682 | Bryan et al. | Aug 2002 | B1 |
| 6440565 | Kim et al. | Aug 2002 | B1 |
| 6444326 | Smith | Sep 2002 | B1 |
| 6461334 | Buch-Rasmussen et al. | Oct 2002 | B1 |
| 6465056 | Chabrecek et al. | Oct 2002 | B1 |
| 6482531 | Timmons et al. | Nov 2002 | B1 |
| 6547868 | Belmares et al. | Apr 2003 | B1 |
| 6599594 | Walther et al. | Jul 2003 | B1 |
| 6645378 | Liu et al. | Nov 2003 | B1 |
| 6660338 | Hargreaves | Dec 2003 | B1 |
| 6686035 | Jiang et al. | Feb 2004 | B2 |
| 6706408 | Jelle | Mar 2004 | B2 |
| 6743516 | Murphy et al. | Jun 2004 | B2 |
| 6763437 | Nguyen et al. | Jul 2004 | B1 |
| 6783800 | Saito et al. | Aug 2004 | B2 |
| 6844028 | Mao et al. | Jan 2005 | B2 |
| 6873387 | Hokazono et al. | Mar 2005 | B2 |
| 6905772 | Shoup et al. | Jun 2005 | B2 |
| 6916541 | Pantano et al. | Jul 2005 | B2 |
| 6991826 | Pellerite et al. | Jan 2006 | B2 |
| 7067194 | Mao et al. | Jun 2006 | B2 |
| 7138186 | Luten, III | Nov 2006 | B2 |
| 7250214 | Walter et al. | Jul 2007 | B2 |
| 7285674 | Palma et al. | Oct 2007 | B2 |
| 7294365 | Hayakawa et al. | Nov 2007 | B2 |
| 7351477 | Yamaya et al. | Apr 2008 | B2 |
| 7387836 | Gianolio et al. | Jun 2008 | B2 |
| 7413774 | Kobrin et al. | Aug 2008 | B2 |
| 7419636 | Aker et al. | Sep 2008 | B2 |
| 7419699 | Kitada et al. | Sep 2008 | B2 |
| 7431969 | Gleason et al. | Oct 2008 | B2 |
| 7553514 | Fan et al. | Jun 2009 | B2 |
| 7629029 | Mao et al. | Dec 2009 | B2 |
| 7638167 | Kobrin et al. | Dec 2009 | B2 |
| 7662936 | Kadkhodayan et al. | Feb 2010 | B2 |
| 7687239 | Goldberg et al. | Mar 2010 | B2 |
| 7695775 | Kobrin et al. | Apr 2010 | B2 |
| 7732216 | Nochumson et al. | Jun 2010 | B2 |
| 7736735 | Kanamori et al. | Jun 2010 | B2 |
| 7776396 | Kobrin et al. | Aug 2010 | B2 |
| 7785649 | Jung et al. | Aug 2010 | B2 |
| 7815922 | Chaney et al. | Oct 2010 | B2 |
| 7842393 | Kuzuya et al. | Nov 2010 | B2 |
| 7879396 | Kobrin et al. | Feb 2011 | B2 |
| 7901744 | Denes et al. | Mar 2011 | B2 |
| 7935489 | O'Neill et al. | May 2011 | B2 |
| 7935659 | Nova et al. | May 2011 | B2 |
| 7955656 | Murayama et al. | Jun 2011 | B2 |
| 7955704 | Lowery et al. | Jun 2011 | B2 |
| 8008225 | Henze et al. | Aug 2011 | B2 |
| 8025915 | Haines et al. | Sep 2011 | B2 |
| 8062881 | Bookbinder et al. | Nov 2011 | B2 |
| 8105821 | McGall et al. | Jan 2012 | B2 |
| 8147954 | Lee et al. | Apr 2012 | B2 |
| 8163354 | Dang et al. | Apr 2012 | B2 |
| 8178168 | O'Neill et al. | May 2012 | B2 |
| 8178602 | Mao et al. | May 2012 | B2 |
| 8323166 | Haines et al. | Dec 2012 | B2 |
| 8349408 | Dulka et al. | Jan 2013 | B2 |
| 8366814 | Jones et al. | Feb 2013 | B2 |
| 8404621 | Ikeda et al. | Mar 2013 | B2 |
| 8512864 | Konno et al. | Aug 2013 | B2 |
| 8557748 | Ikeda et al. | Oct 2013 | B2 |
| 8580355 | Durandeau et al. | Nov 2013 | B2 |
| 8652588 | Teer et al. | Feb 2014 | B2 |
| 8668972 | Lewis et al. | Mar 2014 | B2 |
| 8691104 | Greer et al. | Apr 2014 | B2 |
| 8709588 | Cadet et al. | Apr 2014 | B2 |
| 8741158 | Aytug et al. | Jun 2014 | B2 |
| 8778278 | Xiong et al. | Jul 2014 | B2 |
| 8784565 | Hillabrand et al. | Jul 2014 | B2 |
| 8795787 | Jehle | Aug 2014 | B2 |
| 8841070 | Harnack et al. | Sep 2014 | B2 |
| 8992590 | Ott et al. | Mar 2015 | B2 |
| 8993479 | Zuilhof et al. | Mar 2015 | B2 |
| 9034660 | Boday et al. | May 2015 | B2 |
| 9075189 | West | Jul 2015 | B2 |
| 9108012 | Pryce Lewis et al. | Aug 2015 | B2 |
| 9175026 | Garrell et al. | Nov 2015 | B2 |
| 9255929 | Jiang et al. | Feb 2016 | B2 |
| 9272095 | Felts et al. | Mar 2016 | B2 |
| 9308520 | Ekeroth | Apr 2016 | B2 |
| 9340880 | Mattzela | May 2016 | B2 |
| 9364853 | Chen | Jun 2016 | B2 |
| 9388315 | Hoshino | Jul 2016 | B2 |
| 9445504 | Kang et al. | Sep 2016 | B2 |
| 9475225 | Giraud et al. | Oct 2016 | B2 |
| 9523004 | Hervieu et al. | Dec 2016 | B2 |
| 9533006 | Jiang et al. | Jan 2017 | B2 |
| 9541480 | Chang et al. | Jan 2017 | B2 |
| 9556360 | McGall et al. | Jan 2017 | B2 |
| 9777368 | Smith et al. | Oct 2017 | B2 |
| 9915001 | Yuan et al. | Mar 2018 | B2 |
| 9925521 | Wyndham et al. | Mar 2018 | B2 |
| 9926203 | Zhou | Mar 2018 | B2 |
| 9975143 | Smith et al. | May 2018 | B2 |
| 9999901 | Boscher et al. | Jun 2018 | B2 |
| 10472769 | Tuteja et al. | Nov 2019 | B2 |
| 10604660 | Smith et al. | Mar 2020 | B2 |
| 10813609 | Goto et al. | Oct 2020 | B2 |
| 10813610 | Yoshida et al. | Oct 2020 | B2 |
| 10814253 | Lipkens et al. | Oct 2020 | B2 |
| 10814305 | Liao et al. | Oct 2020 | B2 |
| 10814319 | Dasgupta et al. | Oct 2020 | B2 |
| 10814320 | Le et al. | Oct 2020 | B2 |
| 10814740 | Wilhide | Oct 2020 | B2 |
| 10815247 | Flemming et al. | Oct 2020 | B2 |
| 10815269 | Maloisel et al. | Oct 2020 | B2 |
| 10816115 | Buerger et al. | Oct 2020 | B2 |
| 10816476 | Nunney et al. | Oct 2020 | B2 |
| 10816487 | Matney et al. | Oct 2020 | B2 |
| 10816515 | Hollnagel et al. | Oct 2020 | B2 |
| 10816518 | Jarrold et al. | Oct 2020 | B2 |
| 10816786 | Douglas-Hamilton et al. | Oct 2020 | B2 |
| 10818485 | Yamaguchi | Oct 2020 | B2 |
| 10818486 | Corr et al. | Oct 2020 | B2 |
| 10828665 | Stiff-Roberts et al. | Nov 2020 | B2 |
| 10876202 | Verbeck, IV et al. | Dec 2020 | B2 |
| 10876210 | Claussen et al. | Dec 2020 | B1 |
| 10895009 | Carr et al. | Jan 2021 | B2 |
| 10912714 | Weikart et al. | Feb 2021 | B2 |
| 11435327 | Matsumoto | Sep 2022 | B2 |
| 11442064 | Koskinen et al. | Sep 2022 | B2 |
| 11511213 | Belanger et al. | Nov 2022 | B2 |
| 20010021446 | Takematsu et al. | Sep 2001 | A1 |
| 20020003109 | Gjerde et al. | Jan 2002 | A1 |
| 20020016250 | Hayakawa et al. | Feb 2002 | A1 |
| 20020020053 | Fonash et al. | Feb 2002 | A1 |
| 20020026899 | McLaughlin et al. | Mar 2002 | A1 |
| 20020142621 | Wang | Oct 2002 | A1 |
| 20020172938 | Cuomo et al. | Nov 2002 | A1 |
| 20020195950 | Mikhael et al. | Dec 2002 | A1 |
| 20030049860 | Cholewa | Mar 2003 | A1 |
| 20030057154 | Gjerde et al. | Mar 2003 | A1 |
| 20030059573 | Timmons et al. | Mar 2003 | A1 |
| 20030109062 | Inomata et al. | Jun 2003 | A1 |
| 20030113477 | Timmons et al. | Jun 2003 | A1 |
| 20030138645 | Gleason et al. | Jul 2003 | A1 |
| 20040261703 | Kobrin et al. | Dec 2004 | A1 |
| 20050118595 | Lahann | Jun 2005 | A1 |
| 20050164402 | Belisle et al. | Jul 2005 | A1 |
| 20050214803 | Wang | Sep 2005 | A1 |
| 20060073521 | Saito et al. | Apr 2006 | A1 |
| 20060110594 | Frutos et al. | May 2006 | A1 |
| 20060213441 | Kobrin et al. | Sep 2006 | A1 |
| 20060219598 | Cody et al. | Oct 2006 | A1 |
| 20060251795 | Kobrin et al. | Nov 2006 | A1 |
| 20070031854 | Katsilometes | Feb 2007 | A1 |
| 20070048747 | Leslie et al. | Mar 2007 | A1 |
| 20070065591 | Parbhu | Mar 2007 | A1 |
| 20070122308 | Ikeda et al. | May 2007 | A1 |
| 20070172666 | Denes et al. | Jul 2007 | A1 |
| 20070254378 | Zhang et al. | Nov 2007 | A1 |
| 20080041105 | Hahn et al. | Feb 2008 | A1 |
| 20080075960 | Pocius et al. | Mar 2008 | A1 |
| 20080085528 | Marcinkeviciene et al. | Apr 2008 | A1 |
| 20080170230 | Gerion | Jul 2008 | A1 |
| 20080188010 | Saitoh et al. | Aug 2008 | A1 |
| 20080248589 | Belisle et al. | Oct 2008 | A1 |
| 20080312356 | Kobrin et al. | Dec 2008 | A1 |
| 20090020712 | Matsumoto | Jan 2009 | A1 |
| 20090078633 | Chen et al. | Mar 2009 | A1 |
| 20090081371 | Minami et al. | Mar 2009 | A1 |
| 20090137526 | Jubert et al. | May 2009 | A1 |
| 20090162571 | Haines et al. | Jun 2009 | A1 |
| 20090176084 | Yoshihara et al. | Jul 2009 | A1 |
| 20090206034 | Nakajima | Aug 2009 | A1 |
| 20090286435 | Badyal et al. | Nov 2009 | A1 |
| 20090318609 | Badyal et al. | Dec 2009 | A1 |
| 20100038298 | Angelini et al. | Feb 2010 | A1 |
| 20100080903 | Tamitsuji et al. | Apr 2010 | A1 |
| 20100178512 | Giesenberg et al. | Jul 2010 | A1 |
| 20100196724 | Yamasaki et al. | Aug 2010 | A1 |
| 20100200207 | Fukuda et al. | Aug 2010 | A1 |
| 20100203646 | Larsen et al. | Aug 2010 | A1 |
| 20100282077 | Jones et al. | Nov 2010 | A1 |
| 20100285596 | Yu et al. | Nov 2010 | A1 |
| 20100330278 | Choi et al. | Dec 2010 | A1 |
| 20110000658 | Tanaka et al. | Jan 2011 | A1 |
| 20110062047 | Haines et al. | Mar 2011 | A1 |
| 20110120213 | Hirayama et al. | May 2011 | A1 |
| 20110120940 | Allen et al. | May 2011 | A1 |
| 20110189493 | Ott et al. | Aug 2011 | A1 |
| 20110295033 | Mayorga et al. | Dec 2011 | A1 |
| 20120069295 | Fukagawa et al. | Mar 2012 | A1 |
| 20120100546 | Lowery, Jr. et al. | Apr 2012 | A1 |
| 20120123345 | Felts et al. | May 2012 | A1 |
| 20120132794 | Buchanan et al. | May 2012 | A1 |
| 20120178848 | Adkinson et al. | Jul 2012 | A1 |
| 20120219697 | Chen | Aug 2012 | A1 |
| 20120219727 | Gandhiraman et al. | Aug 2012 | A1 |
| 20120251797 | Smith et al. | Oct 2012 | A1 |
| 20120252709 | Felts et al. | Oct 2012 | A1 |
| 20120288717 | Mao et al. | Nov 2012 | A1 |
| 20130004780 | Hervieu et al. | Jan 2013 | A1 |
| 20130025503 | Park et al. | Jan 2013 | A1 |
| 20130029138 | Benard et al. | Jan 2013 | A1 |
| 20130090260 | Nova et al. | Apr 2013 | A1 |
| 20130136937 | Fujii et al. | May 2013 | A1 |
| 20130157062 | Kihara et al. | Jun 2013 | A1 |
| 20130174642 | Bourlon et al. | Jul 2013 | A1 |
| 20130244025 | Smith et al. | Sep 2013 | A1 |
| 20130266762 | Mayers et al. | Oct 2013 | A1 |
| 20130337226 | Curran et al. | Dec 2013 | A1 |
| 20140004022 | Sagona et al. | Jan 2014 | A1 |
| 20140065368 | Aytug et al. | Mar 2014 | A1 |
| 20140147631 | Yang et al. | May 2014 | A1 |
| 20140154399 | Weikart et al. | Jun 2014 | A1 |
| 20140187666 | Aizenberg et al. | Jul 2014 | A1 |
| 20140202355 | Hoshino | Jul 2014 | A1 |
| 20140273080 | Apffel, Jr. | Sep 2014 | A1 |
| 20140287240 | Murotani et al. | Sep 2014 | A1 |
| 20140299538 | Gleason et al. | Oct 2014 | A1 |
| 20140318748 | Svensson et al. | Oct 2014 | A1 |
| 20140323981 | Giraud et al. | Oct 2014 | A1 |
| 20140342954 | Ingber et al. | Nov 2014 | A1 |
| 20140357091 | Mattzela | Dec 2014 | A1 |
| 20140370300 | Smith | Dec 2014 | A1 |
| 20150021339 | Felts et al. | Jan 2015 | A1 |
| 20150024152 | Carr | Jan 2015 | A1 |
| 20150030885 | Smith | Jan 2015 | A1 |
| 20150064376 | Smith et al. | Mar 2015 | A1 |
| 20150064451 | Kalaga et al. | Mar 2015 | A1 |
| 20150098084 | Felts et al. | Apr 2015 | A1 |
| 20150118502 | Mitsuhashi et al. | Apr 2015 | A1 |
| 20150118504 | Ohshita et al. | Apr 2015 | A1 |
| 20150122365 | Carr et al. | May 2015 | A1 |
| 20150152124 | Mori et al. | Jun 2015 | A1 |
| 20150175814 | Aizenberg et al. | Jun 2015 | A1 |
| 20150209846 | Aizanberg et al. | Jul 2015 | A1 |
| 20150210951 | Aizenberg et al. | Jul 2015 | A1 |
| 20150232806 | Jung et al. | Aug 2015 | A1 |
| 20150239773 | Aytug | Aug 2015 | A1 |
| 20150247051 | Ha et al. | Sep 2015 | A1 |
| 20150273522 | Boscher et al. | Oct 2015 | A1 |
| 20150283307 | Smith et al. | Oct 2015 | A1 |
| 20150298165 | Smith | Oct 2015 | A1 |
| 20150307525 | Higano et al. | Oct 2015 | A1 |
| 20150307719 | Mitsuhashi et al. | Oct 2015 | A1 |
| 20150309216 | Fournand | Oct 2015 | A1 |
| 20150322272 | Pokroy et al. | Nov 2015 | A1 |
| 20150329725 | Liu | Nov 2015 | A1 |
| 20160002488 | Takao et al. | Jan 2016 | A1 |
| 20160002489 | Gleason et al. | Jan 2016 | A1 |
| 20160017397 | Roy et al. | Jan 2016 | A1 |
| 20160038972 | Lu | Feb 2016 | A1 |
| 20160040039 | Yamane et al. | Feb 2016 | A1 |
| 20160059260 | Smith et al. | Mar 2016 | A1 |
| 20160074862 | Breaux et al. | Mar 2016 | A1 |
| 20160168021 | Goh et al. | Jun 2016 | A1 |
| 20160200941 | Liu et al. | Jul 2016 | A1 |
| 20160231594 | Ang et al. | Aug 2016 | A1 |
| 20160243308 | Giraud et al. | Aug 2016 | A1 |
| 20160251261 | Bureau | Sep 2016 | A1 |
| 20160289824 | Mattzela et al. | Oct 2016 | A1 |
| 20160302723 | Chen | Oct 2016 | A1 |
| 20160340544 | Katsukawa et al. | Nov 2016 | A1 |
| 20170001956 | Chau et al. | Jan 2017 | A1 |
| 20170044315 | Mitsuhashi et al. | Feb 2017 | A1 |
| 20170173223 | Delaney, Jr. et al. | Jun 2017 | A1 |
| 20180049644 | Themelis | Feb 2018 | A1 |
| 20180258529 | Vezza | Sep 2018 | A1 |
| 20180357402 | Omata et al. | Dec 2018 | A1 |
| 20190032201 | Smith et al. | Jan 2019 | A1 |
| 20190077966 | Koguchi et al. | Mar 2019 | A1 |
| 20190086371 | Lauber | Mar 2019 | A1 |
| 20190170705 | Wyndham | Jun 2019 | A1 |
| 20190271711 | Egan et al. | Sep 2019 | A1 |
| 20190292220 | Birdsall | Sep 2019 | A1 |
| 20190390329 | Carr et al. | Dec 2019 | A1 |
| 20200024155 | Kano et al. | Jan 2020 | A1 |
| 20200024156 | Kano et al. | Jan 2020 | A1 |
| 20200024157 | Kano et al. | Jan 2020 | A1 |
| 20200025729 | Milburn et al. | Jan 2020 | A1 |
| 20200062615 | Rajagopalan et al. | Feb 2020 | A1 |
| 20200109297 | McDaniel | Apr 2020 | A1 |
| 20200189938 | Kano et al. | Jun 2020 | A1 |
| 20200215457 | DeLano et al. | Jul 2020 | A1 |
| 20200239641 | Kawakami et al. | Jul 2020 | A1 |
| 20200328073 | Peterson et al. | Oct 2020 | A1 |
| 20200332801 | Kimura | Oct 2020 | A1 |
| 20200333265 | Doki et al. | Oct 2020 | A1 |
| 20200333369 | Toyoda et al. | Oct 2020 | A1 |
| 20200334792 | Themelis | Oct 2020 | A1 |
| 20200335902 | Tanaka | Oct 2020 | A1 |
| 20200337659 | Sano et al. | Oct 2020 | A1 |
| 20200338528 | Dong et al. | Oct 2020 | A1 |
| 20200339322 | Christensen et al. | Oct 2020 | A1 |
| 20200339665 | Bruhlmann et al. | Oct 2020 | A1 |
| 20200339931 | Bremer et al. | Oct 2020 | A1 |
| 20200339977 | Lebofsky et al. | Oct 2020 | A1 |
| 20200339980 | Dellinger et al. | Oct 2020 | A1 |
| 20200340047 | Mollerup | Oct 2020 | A1 |
| 20200340468 | Kuntz et al. | Oct 2020 | A1 |
| 20200340889 | Mlcak et al. | Oct 2020 | A1 |
| 20200340890 | Mlcak | Oct 2020 | A1 |
| 20200340910 | Handique | Oct 2020 | A1 |
| 20200340946 | Bateman et al. | Oct 2020 | A1 |
| 20200340949 | Mlcak et al. | Oct 2020 | A1 |
| 20200340950 | Mlcak et al. | Oct 2020 | A1 |
| 20200340956 | Ortmann et al. | Oct 2020 | A1 |
| 20200340959 | Schultz et al. | Oct 2020 | A1 |
| 20200340961 | Kunimura | Oct 2020 | A1 |
| 20200340982 | Levin et al. | Oct 2020 | A1 |
| 20200341253 | Foelling | Oct 2020 | A1 |
| 20200341255 | Chan | Oct 2020 | A1 |
| 20200341259 | Chan et al. | Oct 2020 | A1 |
| 20200341278 | Tanaka | Oct 2020 | A1 |
| 20200341378 | Wolterink et al. | Oct 2020 | A1 |
| 20200342326 | Rahnama Moghaddam | Oct 2020 | A1 |
| 20200342672 | Schmelig et al. | Oct 2020 | A1 |
| 20200343082 | Richardson et al. | Oct 2020 | A1 |
| 20200348307 | Beierle et al. | Nov 2020 | A1 |
| 20200365237 | Madden et al. | Nov 2020 | A1 |
| 20200375846 | Chang et al. | Dec 2020 | A1 |
| 20210009817 | Poulet et al. | Jan 2021 | A1 |
| 20210009883 | Tuteja et al. | Jan 2021 | A1 |
| 20210032157 | Czihal et al. | Feb 2021 | A1 |
| 20210061049 | Lekon et al. | Mar 2021 | A1 |
| 20210098233 | Kapoor et al. | Apr 2021 | A1 |
| 20210101176 | Baltazar et al. | Apr 2021 | A1 |
| 20210108252 | Beverly | Apr 2021 | A1 |
| 20210255196 | Birdsall | Aug 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2020244497 | Oct 2020 | AU |
| 2538124 | Jul 2010 | CA |
| 2881275 | Oct 2020 | CA |
| 2855353 | Jan 2021 | CA |
| 104327663 | Feb 2015 | CN |
| 109225113 | Jan 2019 | CN |
| 109608680 | Apr 2019 | CN |
| 111471977 | Jul 2020 | CN |
| 111560172 | Aug 2020 | CN |
| 111848755 | Oct 2020 | CN |
| 111855826 | Oct 2020 | CN |
| 111855827 | Oct 2020 | CN |
| 111863585 | Oct 2020 | CN |
| 111944153 | Nov 2020 | CN |
| 112011055 | Dec 2020 | CN |
| 112264272 | Jan 2021 | CN |
| 1816155 | Jun 2011 | EP |
| 2587258 | May 2013 | EP |
| 2608219 | Mar 2015 | EP |
| 2915833 | Sep 2015 | EP |
| 3573646 | Dec 2019 | EP |
| 3633366 | Apr 2020 | EP |
| 2403621 | Oct 2020 | EP |
| 2798664 | Oct 2020 | EP |
| 2834837 | Oct 2020 | EP |
| 2900819 | Oct 2020 | EP |
| 3006980 | Oct 2020 | EP |
| 3060325 | Oct 2020 | EP |
| 3131657 | Oct 2020 | EP |
| 3139150 | Oct 2020 | EP |
| 3169232 | Oct 2020 | EP |
| 3169424 | Oct 2020 | EP |
| 3273674 | Oct 2020 | EP |
| 3344317 | Oct 2020 | EP |
| 3399074 | Oct 2020 | EP |
| 3545085 | Oct 2020 | EP |
| 3727152 | Oct 2020 | EP |
| 3727637 | Oct 2020 | EP |
| 3727679 | Oct 2020 | EP |
| 3727690 | Oct 2020 | EP |
| 3728046 | Oct 2020 | EP |
| 3728581 | Oct 2020 | EP |
| 3728621 | Oct 2020 | EP |
| 3728633 | Oct 2020 | EP |
| 3729055 | Oct 2020 | EP |
| 3729071 | Oct 2020 | EP |
| 3729077 | Oct 2020 | EP |
| 3729083 | Oct 2020 | EP |
| 3729162 | Oct 2020 | EP |
| 3729487 | Oct 2020 | EP |
| 3729488 | Oct 2020 | EP |
| 3730119 | Oct 2020 | EP |
| 3730324 | Oct 2020 | EP |
| 3730406 | Oct 2020 | EP |
| 3730538 | Oct 2020 | EP |
| 3730599 | Oct 2020 | EP |
| 3730922 | Oct 2020 | EP |
| 3730923 | Oct 2020 | EP |
| 3730927 | Oct 2020 | EP |
| 3731393 | Oct 2020 | EP |
| 3749719 | Dec 2020 | EP |
| 3788181 | Mar 2021 | EP |
| 3095337 | Oct 2020 | FR |
| 2108403 | May 1983 | GB |
| 2429428 | Feb 2007 | GB |
| 2481687 | Jan 2012 | GB |
| 2490243 | Oct 2012 | GB |
| 2501803 | Nov 2013 | GB |
| 2531126 | Apr 2016 | GB |
| 2549248 | Oct 2017 | GB |
| 2534477 | Oct 2020 | GB |
| 2574723 | Oct 2020 | GB |
| 174122 | Sep 2011 | IL |
| 239213 | Mar 2020 | IL |
| 253518 | Jun 2020 | IL |
| 262854 | Jun 2020 | IL |
| 2012232870 | Nov 2012 | JP |
| 2020507460 | Mar 2020 | JP |
| 2020507462 | Mar 2020 | JP |
| 2020507466 | Mar 2020 | JP |
| 2020510522 | Apr 2020 | JP |
| 6770727 | Oct 2020 | JP |
| 6771390 | Oct 2020 | JP |
| 6771801 | Oct 2020 | JP |
| 6772721 | Oct 2020 | JP |
| 6772764 | Oct 2020 | JP |
| 6772953 | Oct 2020 | JP |
| 6773138 | Oct 2020 | JP |
| 6773236 | Oct 2020 | JP |
| 2020169857 | Oct 2020 | JP |
| 2020171429 | Oct 2020 | JP |
| 2020171482 | Oct 2020 | JP |
| 2020171483 | Oct 2020 | JP |
| 2020171484 | Oct 2020 | JP |
| 2020171882 | Oct 2020 | JP |
| 2020172518 | Oct 2020 | JP |
| 2020172703 | Oct 2020 | JP |
| 2020173192 | Oct 2020 | JP |
| 2020173427 | Oct 2020 | JP |
| 2020176195 | Oct 2020 | JP |
| 2020177669 | Oct 2020 | JP |
| 2020530329 | Oct 2020 | JP |
| 2020530909 | Oct 2020 | JP |
| 2020536764 | Dec 2020 | JP |
| 960007179 | May 1996 | KR |
| 20000019936 | Apr 2000 | KR |
| 20060130959 | Dec 2006 | KR |
| 20080071942 | Aug 2008 | KR |
| 20090103323 | Oct 2009 | KR |
| 20120007817 | Jan 2012 | KR |
| 20130020869 | Mar 2013 | KR |
| 20140082838 | Jul 2014 | KR |
| 101711786 | Mar 2017 | KR |
| 20170021957 | Mar 2017 | KR |
| 101742683 | Jun 2017 | KR |
| 20180008427 | Jan 2018 | KR |
| 20200139842 | Dec 2020 | KR |
| 20210008523 | Jan 2021 | KR |
| 102218186 | Feb 2021 | KR |
| 20210013582 | Feb 2021 | KR |
| 202031738 | Sep 2020 | TW |
| 202039644 | Nov 2020 | TW |
| 199119982 | Dec 1991 | WO |
| 1998017407 | Apr 1998 | WO |
| 1999040038 | Aug 1999 | WO |
| 199951773 | Oct 1999 | WO |
| 200032044 | Jun 2000 | WO |
| 200168240 | Sep 2001 | WO |
| 2002085250 | Oct 2002 | WO |
| 2002085330 | Oct 2002 | WO |
| 2003104394 | Dec 2003 | WO |
| 2006015982 | Feb 2006 | WO |
| 2006121295 | Nov 2006 | WO |
| 2007081387 | Jul 2007 | WO |
| 2007117191 | Oct 2007 | WO |
| 2007117213 | Oct 2007 | WO |
| 2007117214 | Oct 2007 | WO |
| 2009007150 | Jan 2009 | WO |
| 2010009311 | Jan 2010 | WO |
| 2010135660 | Nov 2010 | WO |
| 2012170549 | Dec 2012 | WO |
| 2013064754 | May 2013 | WO |
| 2014104495 | Jul 2014 | WO |
| 2014104573 | Jul 2014 | WO |
| 2014164928 | Oct 2014 | WO |
| 2015050449 | Apr 2015 | WO |
| 2015054652 | Apr 2015 | WO |
| 2015134488 | Sep 2015 | WO |
| 2016100923 | Jun 2016 | WO |
| 2016114850 | Jul 2016 | WO |
| 2016125272 | Aug 2016 | WO |
| 2016160702 | Oct 2016 | WO |
| 2016166816 | Oct 2016 | WO |
| 2017040623 | Mar 2017 | WO |
| 2017053891 | Mar 2017 | WO |
| 2017060991 | Apr 2017 | WO |
| 2017072893 | May 2017 | WO |
| 2017087032 | May 2017 | WO |
| 2017098758 | Jun 2017 | WO |
| 2017143246 | Aug 2017 | WO |
| 2017171546 | Oct 2017 | WO |
| 2017189357 | Nov 2017 | WO |
| 2017210223 | Dec 2017 | WO |
| 2018072862 | Apr 2018 | WO |
| 2018146318 | Aug 2018 | WO |
| 2018202935 | Nov 2018 | WO |
| 2019053693 | Mar 2019 | WO |
| 2019063482 | Apr 2019 | WO |
| 2019101980 | May 2019 | WO |
| 2019116619 | Jun 2019 | WO |
| 2019122100 | Jun 2019 | WO |
| 2019126130 | Jun 2019 | WO |
| 2019130536 | Jul 2019 | WO |
| 2019138705 | Jul 2019 | WO |
| 2019150573 | Aug 2019 | WO |
| 2019152724 | Aug 2019 | WO |
| 2019154758 | Aug 2019 | WO |
| 2019155543 | Aug 2019 | WO |
| 2019155545 | Aug 2019 | WO |
| 2019165297 | Aug 2019 | WO |
| 2019168989 | Sep 2019 | WO |
| 2019171085 | Sep 2019 | WO |
| 2019175441 | Sep 2019 | WO |
| 2019176081 | Sep 2019 | WO |
| 2019180045 | Sep 2019 | WO |
| 2019185607 | Oct 2019 | WO |
| 2019186999 | Oct 2019 | WO |
| 2019191269 | Oct 2019 | WO |
| 2019191587 | Oct 2019 | WO |
| 2019193558 | Oct 2019 | WO |
| 2019198280 | Oct 2019 | WO |
| 2019200306 | Oct 2019 | WO |
| 2019212799 | Nov 2019 | WO |
| 2019218088 | Nov 2019 | WO |
| 2019224201 | Nov 2019 | WO |
| 2019224540 | Nov 2019 | WO |
| 2019229171 | Dec 2019 | WO |
| 2019238469 | Dec 2019 | WO |
| 2019241394 | Dec 2019 | WO |
| 2020068174 | Apr 2020 | WO |
| 2020095566 | May 2020 | WO |
| 2020104521 | May 2020 | WO |
| 2020174402 | Sep 2020 | WO |
| 2020213061 | Oct 2020 | WO |
| 2020213101 | Oct 2020 | WO |
| 2020213209 | Oct 2020 | WO |
| 2020216966 | Oct 2020 | WO |
| 2020219451 | Oct 2020 | WO |
| 2020219605 | Oct 2020 | WO |
| 2020219659 | Oct 2020 | WO |
| 2020219667 | Oct 2020 | WO |
| 2020219671 | Oct 2020 | WO |
| 2020219784 | Oct 2020 | WO |
| 2020219869 | Oct 2020 | WO |
| 2021019220 | Feb 2021 | WO |
| 2021061049 | Apr 2021 | WO |
| 2021072245 | Apr 2021 | WO |
| Entry |
|---|
| Vaidya, Shyam V., et al. “Protein-resistant properties of a chemical vapor deposited alkyl-functional carboxysilane coating characterized using quartz crystal microbalance.” Applied Surface Science 364 (2016): 896-908. (Year: 2016). |
| Biba. “Chromatographic Analysis and Separation of Short RNA Oligonucleotides with Novel Liquid Chromatography Methods.” Drexel University Thesis, Doctor of Philosophy. Jun. 2014. |
| International Search Report and Written Opinion issued in International Application No. PCT/IB2021/050315 dated Apr. 23, 2021. |
| Sinha et al. “Analysis and Purification of Synthetic Nucleic Acids Using HPLC.” Curr. Protoc. Nucleic Acid Chem. (2015). 61: 10.5.1-10.5.39. |
| “High Purity Coatings, the Secret Weapon in Semiconductor Manufacturing.” SilcoTek, Dec. 12, 2014. |
| “How to Identify and Prevent Fouling (HPL)”. SilcoTek. Jun. 22, 2017. |
| “Solving Surface Fouling with New Non-Stick CVD Coatings.” SilcoTek. Aug. 31, 2017. |
| “Specialty Coatings.” https://geniefilters.com/news-room/specialty-coatings. Dec. 29, 2013. |
| “Visit US at Pittcon: Make Your HPLC System Faster & More Reliable.” SilcoTek. Mar. 3, 2017. |
| “What's SilcoTek Talking About at Pittcon 2018.” SilcoTek. Feb. 16, 2018. |
| Electrical Property Characterization of SilcoTek Coatings.′ Retrieved on Jul. 31, 2023. |
| Al-Hamarneh et al. “Synthesis and characterization of di(ethylene glycol) vinyl ether films deposited by atmospheric pressure corona discharge plasma.” Surface Coatings Technol. 234(2013):33-41. |
| Barone et al. “Characterizing the Performance of Surface Modifications that Enhance Sensitivty, Reliability, Reproducibility and Accuracy of Analytical Instruments.” (2011). |
| Barone et al. “Improving Reliability of Analytical and Sampling Systems in Challenges and Corrosive Environments.” (2011). |
| Beigbeder et al. “Marine Fouling Release Silicone/Carbon Nanotube Nanocomposite Coatings: On the Importance of the Nanotube Dispersion State.” J. Nanosci. Nanotech, 10(2010): 2972-2978. |
| BIOCYL™ X1, Dec. 20, 2018. |
| Bischof. “Achieving PEEK-like Performance on Stainless Steel HPLC Components with Bio-Inert CVD Coatings.” SilcoTek. Feb. 28, 2019. |
| Brown et al. “Sampling of gaseous sulfur-containing compounds at low concentrations with a review of best-practice methods for biogas and natural gas applications.” Trends Anal. Chem. 64(2015): 42-52. |
| Buchmeiser. “New synthetic ways for the preparation of high-performance liquid chromatography supports.” J. Chromatogr. A. 918(2001): 233-266. |
| Carretier et al. “Design of PVDF/PEGMA-b-PS-b-PEGMA membranes by VIPS for improved biofouling mitigation.” J. Membrane Sci. 510(2016):355-369. |
| Cheong. “Fritting techniques in chromatography.” J. Sep. Sci. 37(2014): 603-617. |
| Colic et al. “Synergistic Application of Chemical and Electromagnetic Water Treatment in Corrosion and Scale Prevention.” Croatiia Chem. Acta. 71.4(1998): 905-916. |
| Conroy. “Nanostructed surfaces for sening heavy metals and radionuclides in aqueous systems.” Doctorate thesis—Philosophy—The University of Leeds. Oct. 2012. |
| Dursan: An Inert and Corrosion Resistant High Performance CVD Coating. SilcoTek. Retrieved on Jul. 31, 2023. |
| Dursan® and SilcoNert® 2000 Coating Comparison Guide. (2000). |
| Dursan® Coating Data Sheet. Jun. 1, 2021. |
| Dursan® Coating for Improved, Metal-Free Liquid Chromatography. Dec. 20, 2018. |
| Dursan® Data Sheet 2018. |
| Hayes et al. “Core-shell particles: Preparation fundamentals and applications in high performance liquid chromatography.” J. Chromatogr. A. 1357(2014): 36-52. |
| HPLC Hardware. Möller Medical. (2007). |
| Hsieh et al. “Effective Enhancement of Fluorescence Detection Efficiency in Protein Microarray Assays: Application of a Highly Fluorinated Organosilane as the Blocking Agent on the Background Surface by a Facile Vapor-Phase Deposition Process.” Anal. Chem. 81(2009): 7908-7916. |
| International Search Report and Written Opinion issued in International Application No. PCT/IB2021/059534 dated Mar. 10, 2022. |
| Kaliaraj et al. “Bio-inspired YSZ coated titanium by EB-PVD for biomedical applications.” Surface and Coatings Technol. 307(2016): 227-235. |
| Kanavarioti et al. “HPLC methods for purity evaluation of man-made single-stranded RNAs.” Nature. 9(2019): 1019. |
| Kong. “Measuring the Electrostatic Repulsion Forces Beween Glycosaminoglycans Using the Atomic Force Microscope.” Masters Thesis—Department of Materials Science Engineering at Massachusetts Institute of Technology, Sep. 1999. |
| Lauber et al. “Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI-MS Detection.” Anal Chem. 87.10(2015): 5401-9. |
| Lecloux et al. “The safe use of carbon nanotubes in coating applications.” OECD Conference on Benefits of nanomaterials. Paris, Jul. 15-17, 2009. |
| NanoCoatings Product Information. Möller Medical. (2010). |
| Paleologos et al. “Micelle-mediated separation and cloud-point extraction.” Trends Anal. Chem. 24.5(2005): 426-436. |
| Pfaunmiller et al. “Affinity monolith chromatography: A review of principles and recent analytical applications.” Anal. Bionanal. Chem. 405.7(2013): 2133-2145. |
| Pirok et al. “Pratical Approaches to Overcome the Challenges of Comprehensive Two-Dimensional Liquid Chromatography.” LCGC Europe. 31.5(2018): 242-249. |
| Pirok et al. “Recent Developments in Two-Dimensional Liquid Chromatography: Fundamental Improvements for Practical Applications.” Anal. Chem. 91.1(2019): 240-263. |
| Rahimi et al. “Application of copolymer coated frits for solid-phase extraction of poly cyclic aromatic hydrocarbons in water samples.” Anal. Chim. Acta. 836(2014): 45-52. |
| Rivera et al. “Bioinert Versus Biocompatible: The Benefits of Different Column Materials in Liquid Chromatography Separations.” LCGC Suppl. 36.6(2018). |
| Rosmaninho et al. “Modified stainless steel surfaces targeted to reduce fouling—Evaluation of fouling by milk components.” J. Food Engineering. 80(2007): 1176-1187. |
| Shih et al. “Silanization of Stainless-Steel Frits for Use in Trace Metal Analysis by High Performance Liquid Chromatography.” Talanta. 28(1981): 411-414. |
| SilcoTek Coating Properties: A Comprehensive Analysis of Coating Characteristics and Properties. e-book. Retrieved 2023. |
| SilcoTek Intellectual Property, Patents and Trademarks. Retrieved Jul. 31, 2023. |
| SilcoTek® Non-Stick CVD Coatings,. Retrieved Jul. 31, 2023. |
| Sun et al. “Vapor-based Grafting of Crosslinked Poly(N-vinyl pyrrolidone) Coatings with Tuned Hydrophilicity and Anti-Biofouling Properties.” J. Mater. Chem. B. 4(2016): 2669-2678. |
| Technical Program, Agenda of Sessions: Abstract PDF. Pittcon, Atlanta, GA, Mar. 6-10, 2016. |
| Vaidya et al. “Protein-Resistant Properties of SilcoTek's Dursan® Coating.” SilcoTek. (2017). |
| Velox Plus, Dec. 20, 2018. |
| Wyndham et al. “Characterization and Evaluation of C18 HPLC Stationary Phases Based on Ethyl-Bridged Hybrid Organic/Inorganic Particles.” Anal. Chem. 75.24(2003): 6781-6788. |
| Xue et al. “Surface-modified anodic aluminum oxide membrane with hydroxyethyl celluloses as a matrix for bilirubin removal.” J. Chromatog. B. 912(2013):1-7. |
| Yang et al. “Synergistic Prevention of Biofouling in Seawater Desalination by Zwitterionic Surfaces and Low-Level Chloronation.” Adv. Mater. 26(2014):1711-1718. |
| “Carboxy-silane triol.” PubChem, Aug. 12, 2023. |
| “Corrosion Resistant Coating Properties: Extend Product Life, Prevent Contamination.” SilcoTek. 2023. |
| “How Corrosion Resistant Is Dursan? Let's Find Out.” SilcoTek. Jan. 23, 2025. |
| ‘Reliable Sampling & Transfer of Sulfur Passivation vs. Inert Coatings.’ SilcoTek. Jun. 16, 2011. |
| “Silane Coupling Agents: Connecting Acorss Boundaries.” Gelest, Inc. 2014. |
| Barone. “Corrosion Control and Chemically inert nano-coatings for use in refining, petrochemical and analytical equipment industries.” 2021. |
| Barone. “Exciting Developments in Silicon Barrier Coatings for Semicon.” SllcokTek. Jul. 15, 2015. |
| Dursan® Coating Data Sheet. 2022. |
| Gosetti et al. “Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry.” J. Chromatogr. A. 1217(2010): 3929-3937. |
| Ntrouka et al. “The effect of chemotherapeutic agents on contaminated titanium surfaces: a systematic review.” Clin. Oral Impl. Res. 22(2011): 681-690. |
| Waters Quality Parts®, Chromatography Columns and Supplies Catalog. Dec. 2014. |
| Number | Date | Country | |
|---|---|---|---|
| 20210220755 A1 | Jul 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63058737 | Jul 2020 | US | |
| 62962487 | Jan 2020 | US |
